Our laboratory conducts cross-disciplinary studies on ER's molecular mechanisms and disease-driven functions, focusing on four key areas: ER phosphorylation and intrinsic disorder; allosteric domain-domain interaction; methodological development of integrative biophysics; and ER-targeted therapeutic development. To achieve these goals, we employ a comprehensive suite of experimental and computational approaches, supported by excellent resources and close collaborations with laboratories in Cleveland and around the globe.

Nov. 2024: Our work on intrinsic ER disorder has been accepted for publication in Nature.

Oct. 2024: Our first US patent application (Patent No. 12,135,332) has been approved.

July 2024: The Mary Kay Ash Foundation supports our translational work on targeting intrinsic ERalpha disorder!

Jun. 2024: We are invited to present our recent work “Phospho-ERα structure and function” at the Endocrine Society meeting (2024) in Boston, MA.

Feb. 2024: We present new findings on intrinsic ERalpha disorder at the Biophysical Society annual meeting (2024) in Philadelphia, PA.

October 3, 2023: The American Cancer Society is funding our drug discovery project!

September 1, 2021: Our long-term R01 project has been renewed by NIGMS!

Apr. 1, 2021: Great news that our collaborative R01 got funded by NCI (via subcontract)!

Apr. 10, 2020: The JMB 2020 special issue on Integrative Biophysics is completed.

Apr. 1, 2020: Our drug discovery project received a boost via the omnibus grant from the National Cancer Institute!

Feb. 1, 2020: The Breast Cancer Alliance supports our drug repurposing project!

Feb. 5, 2019: We are thrilled that our work on the ER disorder is featured in a commentary preview "Molecular Dissection of the Intrinsically Disordered Estrogen Receptor Alpha-NTD" by Manalastas and Svergun.